Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BNTC Benitec Biopharma

Pre-Mkt 05-28 08:00:50 EDT

11.60

+0.15

+1.31%

High12.01	Low11.48	Vol57.57K
Open11.54	D1 Closing11.45	Amplitude4.59%
Mkt Cap397.36M	Tradable Cap241.87M	Total Shares34.25M
T/O670.96K	T/O Rate0.28%	Tradable Shares20.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BNTC","market":"US","secType":"STK","nameCN":"Benitec Biopharma","latestPrice":11.6,"timestamp":1779912000000,"preClose":11.45,"halted":0,"volume":57566,"delay":0,"changeRate":0.01310043668122274,"floatShares":20850800,"shares":34254907,"eps":-0.933773,"marketStatus":"Pre-Mkt","change":0.15,"latestTime":"05-28 08:00:50 EDT","open":11.54,"high":12.0051,"low":11.48,"amount":670957.92253,"amplitude":0.04586,"askPrice":11.8,"askSize":1,"bidPrice":10.45,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.933773,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779975000000},"marketStatusCode":1,"adr":1,"adrRate":200,"listingDate":1439870400000,"exchange":"NASDAQ","adjPreClose":11.6,"postHourTrading":{"tag":"盘后","latestPrice":11.6,"preClose":11.6,"latestTime":"16:57 EDT","volume":697,"amount":8085.2,"timestamp":1779915431920,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7030532484848429,"impliedVol":0.5637,"impliedVolPercentile":0.424},"requestUrl":"/m/hq/s/BNTC/wiki","defaultTab":"wiki","newsList":[{"id":"2635051833","title":"Benitec Biopharma posts BB-301 gene therapy update for OPMD-related dysphagia","url":"https://stock-news.laohu8.com/highlight/detail?id=2635051833","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635051833?lang=en_us&edition=fundamental","pubTime":"2026-05-16 09:22","pubTimestamp":1778894567,"startTime":"0","endTime":"0","summary":"Benitec highlighted durable clinical responses to investigational gene therapy BB-301 in oculopharyngeal muscular dystrophy patients with dysphagia, citing follow-up at 12 months and 24 months in low-dose Cohort 1.All Cohort 1 study completers met company-defined responder criteria at 12 months in Phase 1b/2a open-label dose-escalation study.Interim data from first patient in higher-dose Cohort 2 at 3 months indicated responder status, with improved depth of response versus Cohort 1 in a preliminary comparison.Program update reiterated no treatment-related severe adverse events reported to date, with FDA Fast Track designation and Orphan Drug designation from FDA and EMA.Benitec positioned BB-301 as only clinical-stage therapy in development designed to treat OPMD-related dysphagia, targeting roughly 15,000 patients across North America, Europe, and Israel.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260516:nNDLbxx1rh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088868","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635088868?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:00","pubTimestamp":1778839200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.,·H World ADR                                     1Q       .45       BMO. ,·RBC Bearings                                     4Q      3.33   8:00 AM. ,·Compugen Ltd.                                   1Q      (.07)  7:00 AM. ,·iQIYI ADR                                         1Q      (.03)  5:00 AM. ,·Modiv Ind Cl C                                   1Q       .01. ,·8x8 Inc.                                        4Q       .08   4:05 PM. ,·Amer Sports                                       1Q       .31   6:00 AM. ,·Bilibili Spon                                   1Q       .17   6:00 AM. ,·Canaan Spon ADR                                  1Q      (.03)      BMO. ,·CAVA Grp                                        1Q       .17   4:10 PM. ,·Ceragon Net                                     1Q       .01   7:00 AM. ,·Eagle Materials                     ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BURL","DE","EDRY","DECK","DOMO","FLO","HD","GCO","ECC","EARN","FATN","AS","ADI","EGHT","BLTE","IQ","ELF","GCTS","GLNG","BZ","CDLR","CAE","CAN","GDS","CPRT","HLNE","BORR","BNTC","HSAI","AAP","CMBT","ENS","BBW","CRVO","HTHT","CAVA","IMVT","CGEN","BIDU","BTM","DAVA","INTU","AGYS","BULL","HAS","BEKE","CRNT","BILI","EXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635877642","title":"Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia","url":"https://stock-news.laohu8.com/highlight/detail?id=2635877642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635877642?lang=en_us&edition=fundamental","pubTime":"2026-05-15 10:55","pubTimestamp":1778813714,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating on May 12. Ritu Baral has given his Buy rating d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/benitec-biopharma-reaffirmed-at-buy-on-strong-cash-runway-and-clear-bb-301-pivotal-path-in-opmd-dysphagia-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/benitec-biopharma-reaffirmed-at-buy-on-strong-cash-runway-and-clear-bb-301-pivotal-path-in-opmd-dysphagia-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BK4097","BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635745692","title":"Benitec Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635745692","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635745692?lang=en_us&edition=fundamental","pubTime":"2026-05-14 22:21","pubTimestamp":1778768509,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc reports results for the quarter ended March 31 - Earnings SummaryBenitec Biopharma Inc BNTC.OQ reported a quarterly adjusted loss of 26 cents per share for the quarter ended Marc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R1NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717782","title":"Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717782","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717782?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:41","pubTimestamp":1778762517,"startTime":"0","endTime":"0","summary":"Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 36.84 percent increase over losses of $(0.38) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52557945/benitec-biopharma-q3-eps-0-24-beats-0-27-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635439712","title":"Benitec Biopharma Q3 net loss narrows as expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2635439712","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635439712?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:10","pubTimestamp":1778760636,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Q3 net loss narrows as expenses fallOverviewUS gene therapy firm's fiscal Q3 net loss narrowed from prior year as expenses fellR&D and G&A expenses declined yr/yr as BB-301 clinical ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0L2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635839712","title":"Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635839712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635839712?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA1WV3K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712485","title":"Benitec Biopharma Inc - Cash and Cash Equivalents $184.8 Mln as of March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712485?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX285204:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712451","title":"Benitec Biopharma Inc - on Track to Engage With FDA Mid-Year to Formalize Bb-301 Pivotal Study Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712451?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX285204:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635128807","title":"Benitec Biopharma Q3 Operating Income USD -13.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635128807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635128807?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX285204:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635024522","title":"Benitec Biopharma initiated with an Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2635024522","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635024522?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:53","pubTimestamp":1778601195,"startTime":"0","endTime":"0","summary":"Evercore ISI initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $25 price target BB-301 represents “an exciting opportuni...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-initiated-with-an-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/benitec-biopharma-initiated-with-an-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634058243","title":"Benitec Biopharma Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2634058243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634058243?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:34","pubTimestamp":1778600040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BNTC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 11:34 ET (15:34 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633468486","title":"Benitec Biopharma Inc  expected to post a loss of 27 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633468486","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633468486?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:46","pubTimestamp":1778255180,"startTime":"0","endTime":"0","summary":"Benitec Biopharma Inc  expected to post a loss of27cents a share - Earnings Preview Benitec Biopharma Inc BNTC.OQ BNTC.O is expected to  show no change in quarterly revenue when it reports  results on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1XU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630031423","title":"Benitec to present interim Phase 1b/2a BB-301 OPMD trial results at ASGCT meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630031423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630031423?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:03","pubTimestamp":1777374220,"startTime":"0","endTime":"0","summary":"Benitec Biopharma scheduled oral presentation of interim results from ongoing Phase 1b/2a first-in-human BB-301 study in oculopharyngeal muscular dystrophy with moderate dysphagia at 2026 ASGCT meeting on May 15, 2026.Update will include 12-month follow-up for first four low-dose Cohort 1 completers, with one patient tracked out to 24 months.Company reported continued durable improvements in low-dose group.Interim readout will also cover first high-dose Cohort 2 patient.Benitec positioned BB-301 as only clinical-stage therapeutic in development targeting dysphagia in patients diagnosed with OPMD.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL2VcfwV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BNTC","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","BK4588","BK4112","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618193411","title":"Benitec Biopharma to host MDA conference industry forum breakfast on BB-301 OPMD trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618193411","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618193411?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:03","pubTimestamp":1773140639,"startTime":"0","endTime":"0","summary":"Benitec will host an Industry Forum Breakfast and presentation at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026. The event is scheduled for 7:00 a.m. to 8:00 a.m. ET at the Hilton Orlando in the Key Largo Room. Materials include a presentation available here.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL1n0fgz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","LU2095319765.USD","SG9999014021.USD","BK4112","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","BK4585","LU0314104364.USD","SG9999014005.SGD","SG9999014013.SGD","BK4139","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618678778","title":"Benitec Biopharma Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618678778","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618678778?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:30","pubTimestamp":1773073800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BNTC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 12:30 ET (16:30 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640291","title":"Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640291","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640291?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251690/0/en/Benitec-Biopharma-Announces-Positive-Interim-Phase-1b-2a-Results-for-High-Dose-BB-301-and-Continued-Durable-Improvements-for-Low-Dose-BB-301-Treatment-at-the-2026-Muscular-Dystroph.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1165135440.EUR","LU2229751404.USD","BNTC","BK4139","LU0070302665.USD","LU2413666426.HKD","TPR","LU0225283273.USD","BK4516","BK4202","IE00BN0W2V16.EUR","LU1721428933.USD","BK4097","LU0347712357.USD","BK4585","IE00BN0W2W23.USD","LU2092937221.SGD","LU2041044095.USD","LU0963586101.USD","LU2413666699.HKD","LU0052756011.USD","LU0310800965.SGD","LU2089279066.USD","IE00BN0W2T93.GBP","A","BK4588","LU1543694498.USD","LU0128525689.USD","MDA","LU0320765489.SGD","BK4547","LU1267930227.SGD","BK4121","BK4567","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613781816","title":"Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613781816","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613781816?lang=en_us&edition=fundamental","pubTime":"2026-02-23 20:01","pubTimestamp":1771848111,"startTime":"0","endTime":"0","summary":"Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLbV5d7q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4585","BNTC","SG9999014005.SGD","SG9999014039.USD","BK4139","BK4588","BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","LU0314104364.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611155620","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2611155620","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611155620?lang=en_us&edition=fundamental","pubTime":"2026-02-13 19:00","pubTimestamp":1770980400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Adv. Auto Parts                                  4Q       .41   6:30 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRZ","AWK","AMPL","BHC","ADAM","ALLE","FLR","CDNS","BNTC","ESNT","CNH","ACCO","BRSP","BLDR","ENB","EXE","EQT","ETOR","FE","ARR","ACLS","CAR","CRSP","CSR","FELE","AERO","ATMU","CCJ","SMWB","BELFA","CIGI","DCH","ENLT","ANDE","ADI","ATRC","CZR","AAP","DTE","AGI","DVN","CE","DFIN","ET","BELFB","BLCO","CEVA","ESI","BBNX","CRNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610922835","title":"Benitec Biopharma Q2 EPS $(0.26) Misses $(0.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2610922835","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610922835?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:07","pubTimestamp":1770905253,"startTime":"0","endTime":"0","summary":"Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by 16.59 percent. This is unchanged from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50575762/benitec-biopharma-q2-eps-0-26-misses-0-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.benitec.com","stockEarnings":[{"period":"1week","weight":0.0555},{"period":"1month","weight":-0.0801},{"period":"3month","weight":0.0366},{"period":"6month","weight":-0.1049},{"period":"1year","weight":-0.1899},{"period":"ytd","weight":-0.1388}],"compareEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0493},{"period":"3month","weight":0.0887},{"period":"6month","weight":0.0981},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.034036},{"month":2,"riseRate":0.545455,"avgChangeRate":0.090462},{"month":3,"riseRate":0.727273,"avgChangeRate":0.04636},{"month":4,"riseRate":0.454545,"avgChangeRate":0.035631},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.049288},{"month":6,"riseRate":0.2,"avgChangeRate":-0.131553},{"month":7,"riseRate":0.5,"avgChangeRate":0.061416},{"month":8,"riseRate":0.4,"avgChangeRate":-0.00465},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.108578},{"month":10,"riseRate":0.636364,"avgChangeRate":-0.026473},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.075117},{"month":12,"riseRate":0.545455,"avgChangeRate":-0.032403}],"exchange":"NASDAQ","name":"Benitec Biopharma","nameEN":"Benitec Biopharma","securityTypeName":"DR","adrRate":"1:200"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Benitec Biopharma,BNTC,Benitec Biopharma股票,Benitec Biopharma股票老虎,Benitec Biopharma股票老虎国际,Benitec Biopharma行情,Benitec Biopharma股票行情,Benitec Biopharma股价,Benitec Biopharma股市,Benitec Biopharma股票价格,Benitec Biopharma股票交易,Benitec Biopharma股票购买,Benitec Biopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Benitec Biopharma(BNTC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Benitec Biopharma(BNTC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction